• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Validated Coding Algorithm Accurately Detects Transthyretin Amyloid Cardiomyopathy in Health Records

by
November 12, 2026
in Health
Reading Time: 6 mins read
0
Validated Coding Algorithm Accurately Detects Transthyretin Amyloid Cardiomyopathy in Health Records

Validated Coding Algorithm Accurately Detects Transthyretin Amyloid Cardiomyopathy in Health Records

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A newly developed claims-based coding algorithm successfully identifies patients with transthyretin amyloid cardiomyopathy across linked administrative records, offering an accurate approach to studying this underrecognized heart disease in large healthcare databases. Transthyretin amyloid cardiomyopathy, commonly abbreviated as ATTR-CM, develops when destabilized transthyretin tetramers dissociate into amyloidogenic monomers that accumulate as toxic amyloid fibrils within the myocardium. This progressive infiltration leads to restrictive cardiomyopathy and severe heart failure. Clinicians recognize two distinct presentations of the condition: wild-type disease, known as ATTRwt-CM, and variant or hereditary disease, referred to as ATTRv-CM. Both forms remain substantially underdiagnosed in clinical practice, with true prevalence estimated to be considerably higher than historic figures suggest. Historically, researchers attempting to evaluate disease burden, healthcare utilization, and clinical outcomes in real-world data have faced substantial barriers due to the absence of a dedicated diagnostic code. To overcome these limitations, investigators designed and evaluated an algorithm named ValidATTR-US, establishing the first United States claims-based coding methodology validated against clinically adjudicated patient records.

The fundamental challenge confronting epidemiologists and health services researchers has been the structural coding complexity within the International Classification of Diseases, Tenth Revision, Clinical Modification system. Although the ICD-10-CM classification incorporates ten separate codes for amyloidosis, none designates transthyretin amyloid cardiomyopathy specifically. Instead, billing personnel and clinicians have historically recorded the disease using nonspecific organ-limited amyloidosis codes in combination with separate codes for cardiomyopathy or heart failure. A recent systematic review emphasized that prior observational studies relied on heterogeneous identification frameworks that differed widely in diagnostic code selection, mandatory concomitant cardiac codes, and secondary exclusion rules. Crucially, none of those previously published United States algorithms had undergone direct validation against clinically confirmed cases. Algorithms formulated too broadly capture patients with unrelated conditions, whereas overly restrictive criteria inadvertently exclude true cases. ValidATTR-US was designed to establish a consistent, standardized definition that minimizes false positives while retaining robust case-finding sensitivity in routine claims and linked electronic health records.

To develop and evaluate the new tool, the investigative team accessed clinical data from the STAnford Research Repository, an electronic health record and claims database compiling information since 1998, as well as the specialized Stanford ATTR-CM Patient Registry. The base source population from the repository comprised 61,908 individuals aged sixty years or older who had at least one recorded diagnosis code for heart failure or cardiomyopathy. From this broad group, the algorithm selected an index cohort consisting of 694 patients who met predefined inclusion and exclusion criteria. For validation, the researchers utilized the Stanford ATTR-CM Patient Registry, which contained 634 patients whose diagnosis had been confirmed through standardized clinical, laboratory, and imaging workups. Because this registry functioned as an internal subset of the broader repository, researchers were able to cross-reference every individual identified by the algorithm against the confirmed registry cases, thereby establishing definitive counts for true positive, false positive, true negative, and false negative outcomes.

The inclusion criteria established for the final ValidATTR-US algorithm require that an individual be at least sixty years of age at the time of diagnosis and possess at least two claims recorded on separate calendar days with specific amyloidosis codes. These acceptable ICD-10-CM diagnostic categories comprise E85.0 for non-neuropathic heredofamilial amyloidosis, E85.1 for neuropathic heredofamilial amyloidosis, E85.2 for unspecified heredofamilial amyloidosis, E85.4 for organ-limited amyloidosis, and E85.82 for wild-type transthyretin amyloid cardiomyopathy. Beyond the qualifying amyloidosis entries, patients had to present with at least two cardiac-related diagnosis codes or have documented evidence of at least one pharmacy claim for tafamidis, a targeted disease-modifying therapy. By incorporating pharmacy claims for tafamidis, the investigators created an operational pathway to capture patients whose clinical treatment was definitively established even if their outpatient diagnostic billing entries were incomplete or fragmented across different institutional encounters.

To maintain rigorous diagnostic specificity, the algorithm applies targeted exclusions that remove clinical conditions prone to administrative misclassification. Patients are excluded if they have more than one claim for multiple myeloma under code C90 or light chain amyloidosis under code E85.81 documented on separate days. A history of hematopoietic stem cell transplantation under code Z94.84 recorded at any point during available follow-up also triggers exclusion. Furthermore, the algorithm removes patients whose organ-limited amyloidosis code E85.4 co-occurs with cerebral amyloid angiopathy under code I68.0, end-stage renal disease under code N18.6, or other disorders of the skin and subcutaneous tissue under code L99. During algorithm optimization, the investigators determined that broad inclusion of nonspecific amyloidosis codes, such as E85.8, E85.89, or E85.9, sharply inflated false-positive identifications without meaningful gains in sensitivity. Conversely, selectively excluding E85.4 when paired with cerebral, renal, or dermatologic conditions eliminated noncardiac amyloid cases without compromising true cardiomyopathy detection.

When assessed against the clinically confirmed validation cohort, ValidATTR-US demonstrated an overall diagnostic accuracy of 99.51 percent, with a 95 percent confidence interval spanning 99.45 to 99.56 percent. The overall specificity reached 99.70 percent, with a 95 percent confidence interval of 99.65 to 99.74 percent, reflecting a low rate of false-positive identification across the evaluated population. Sensitivity was measured at 80.76 percent, with a 95 percent confidence interval ranging from 77.47 to 83.76 percent. In raw numerical counts, the algorithm accurately identified 512 true-positive cases and 61,092 true negatives, while generating 182 false-positive classifications and missing 122 false-negative cases. These findings surpassed the research team’s a priori performance benchmark of achieving greater than 80 percent for both sensitivity and specificity, indicating that the multi-component logic successfully isolates genuine disease cases from large underlying pools of elderly patients managed for general cardiomyopathy or heart failure.

Analysis of baseline clinical and demographic characteristics across the confirmed patient groups revealed distinct phenotypic distributions. Among the 512 true-positive patients captured from the repository index cohort and across the 634 patients in the validation registry, men represented the predominant majority, accounting for 77.32 to 92.50 percent across cohort subgroups, while women represented 7.50 to 22.68 percent. Patient age and racial background diverged noticeably by underlying disease etiology. Individuals diagnosed with wild-type disease presented at an older average age of approximately 79 years and were predominantly White, comprising 83.30 to 83.89 percent of the subgroup. In contrast, patients diagnosed with variant disease presented at a younger average age of 69 to 70 years. Within the variant cohort, Black individuals accounted for 50.77 to 53.61 percent of patients, whereas White individuals constituted 36.92 to 37.11 percent, underscoring substantial epidemiological distinctions between hereditary and acquired manifestations of the disorder.

To evaluate predictive discrimination and the relative contribution of individual diagnostic codes, the investigators conducted ten-fold cross-validation repeated three times, paired with penalized and unpenalized logistic regression modeling. For identifying overall case status, code E85.82 proved to be the strongest individual predictor, yielding an odds ratio of 4.68 with a 95 percent confidence interval of 2.69 to 8.61, followed by code E85.2 with an odds ratio of 2.66 and a confidence interval of 1.21 to 6.33. Female sex was associated with lower odds of confirmed case status, showing an odds ratio of 0.71. Receiver operating characteristic curve analysis revealed an area under the curve of 0.84 for case detection. When classifying genotype among confirmed cases, code E85.2 showed an odds ratio of 77.43, and code E85.1 showed an odds ratio of 29.49 for predicting variant status. Black race demonstrated an odds ratio of 10.42 and younger age an odds ratio of 0.92 per year for variant disease, yielding a genotype discrimination area under the curve of 0.88.

Subgroup evaluations demonstrated that algorithm specificity remained consistently high across diverse demographic categories, ranging between 89 and 100 percent when stratified by age, sex, and race. Overall accuracy across these strata ranged from 68 to 80 percent, whereas sensitivity exhibited wider variability, spanning 38 to 76 percent across subgroups. Preserving high specificity across historically underdiagnosed groups, such as women and Black patients, provides critical protection against misclassification in downstream health economics, comparative effectiveness, and safety studies. Because administrative datasets often incorporate patients with competing plasma cell dyscrasias, high specificity prevents misattributing outcomes from light chain amyloidosis or multiple myeloma to transthyretin disease. Moreover, because ValidATTR-US relies strictly on standard ICD-10-CM codes and outpatient medication billing records, it avoids dependence on specialized echocardiographic parameters, laboratory measurements, or complex natural language processing models, permitting seamless implementation across diverse health plans and electronic databases.

The study authors documented several operational limitations that provide context for interpreting the algorithm’s performance. Because development and validation occurred within a single academic medical center functioning as a tertiary amyloidosis referral facility, the findings represent internal validation, and performance in general community settings remains unestablished. Furthermore, linked electronic health record repositories lack continuous insurance enrollment verification, meaning that patients seeking fragmented care across different health networks may have incomplete diagnostic histories. A small subset of patients possessed tafamidis pharmacy claims without accompanying diagnosis codes, suggesting potential delays between initial prescribing and formal diagnostic coding. In addition, smaller sample sizes within specific racial and genotype strata resulted in wider statistical confidence intervals around certain subgroup estimates. The authors concluded that external validation across multi-center health systems, community clinics, and longitudinal payer databases is warranted to support real-world surveillance and facilitate timely clinical identification.

Subject of Research: Validation of an administrative claims coding algorithm for identifying transthyretin amyloid cardiomyopathy

Article Title: A Validated Transthyretin Amyloid Cardiomyopathy Claims-Based Coding Algorithm: ValidATTR-US

Article References: Jimenez, J. I., Fahed, G., Cai, N., Udall, M., Kitakata, H., & Alexander, K. M. (2026). A Validated Transthyretin Amyloid Cardiomyopathy Claims-Based Coding Algorithm: ValidATTR-US. Cardiology and Therapy. https://doi.org/10.1007/s40119-026-00484-2

Image Credits: AI Generated

DOI: 10.1007/s40119-026-00484-2

Keywords: transthyretin amyloid cardiomyopathy, ATTR-CM, ValidATTR-US, administrative claims, electronic health records, ICD-10-CM, cardiology, diagnostic coding, validation study, tafamidis, Stanford Research Repository, amyloidosis, wild-type ATTR-CM, hereditary ATTR-CM, heart failure, predictive modeling

News Source: Ophelia Keating. (November 12, 2026). Validated Coding Algorithm Accurately Detects Transthyretin Amyloid Cardiomyopathy in Health Records. Scienmag.

Tags: administrative claimsamyloidosisATTR-CMCardiologydiagnostic codingelectronic health recordsheart failurehereditary ATTR-CMICD-10-CMpredictive modelingStanford Research Repositorytafamidistransthyretin amyloid cardiomyopathyvalidation studyValidATTR-USwild-type ATTR-CM
Share12Tweet7Share2ShareShareShare1

Related Posts

Seven-Day Recall Tests Reveal Accelerated Long-Term Memory Forgetting in Multiple Sclerosis

Seven-Day Recall Tests Reveal Accelerated Long-Term Memory Forgetting in Multiple Sclerosis

November 18, 2026
Enhanced Recovery Protocols Reduce Intravenous Infusion Volumes After Pancreaticoduodenectomy Surgery

Enhanced Recovery Protocols Reduce Intravenous Infusion Volumes After Pancreaticoduodenectomy Surgery

November 18, 2026

Five Clinical Measures Help Distinguish Ulcerative Colitis From Crohn’s Disease

November 18, 2026

Adult GLUT1 Deficiency Syndrome Diagnosis Reveals Broad Phenotypic Diversity

November 18, 2026

POPULAR NEWS

  • Geospatial Proxies Reveal Stable Peri-Urban Health Units in Coastal Kenya

    Geospatial Proxies Reveal Stable Peri-Urban Health Units in Coastal Kenya

    29 shares
    Share 12 Tweet 7
  • Herbal Formula Alleviates Knee Osteoarthritis by Inhibiting Inflammatory Signaling in Rabbits

    29 shares
    Share 12 Tweet 7
  • First Single-Cell Microenvironment Atlas Maps Rare Lung Disease Lesions in Women

    29 shares
    Share 12 Tweet 7
  • Dissociative Corticosteroid Vamorolone Shows Differentiated Safety and Efficacy for DMD Treatment

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dual-Targeting CAR T Therapy Demonstrates Durable Activity in High-Risk Extramedullary Myeloma

Seven-Day Recall Tests Reveal Accelerated Long-Term Memory Forgetting in Multiple Sclerosis

Enhanced Recovery Protocols Reduce Intravenous Infusion Volumes After Pancreaticoduodenectomy Surgery

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.